BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32352711)

  • 1. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase.
    Lee HW; Kim EH; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00140. PubMed ID: 32352711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
    Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
    J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
    Choi GH; Kim GA; Choi J; Han S; Lim YS
    Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
    Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
    Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
    Chen CJ; Yang HI; Su J; Jen CL; You SL; Lu SN; Huang GT; Iloeje UH;
    JAMA; 2006 Jan; 295(1):65-73. PubMed ID: 16391218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognosis and management of inactive HBV carriers.
    Invernizzi F; Viganò M; Grossi G; Lampertico P
    Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection.
    Lee HW; Kim SU; Baatarkhuu O; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2808-2810.e2. PubMed ID: 30639778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are serum quantitative hepatitis b surface antigen levels, liver histopathology and viral loads related in chronic hepatitis b-infected patients?
    Balkan A; Namiduru M; Balkan Y; Mete AO; Karaoglan I; Bosnak VK
    Saudi J Gastroenterol; 2016; 22(3):208-14. PubMed ID: 27184639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.